Certolizumab Pegol Provides Sustained Remission and Minimal Disease Activity in Patients with Psoriatic Arthritis Over 4 Years' Treatment

Authors

D van der Heijde
A Deodhar
O FitzGerald
R Fleischmann
D Gladman
Alice B. Gottlieb, New York Medical CollegeFollow
L C. Coates
B Hoepken
L Bauer
L Peterson
M Khraishi
P J. Mease

Author Type(s)

Faculty

Document Type

Abstract

Publication Date

6-2018

DOI

10.1136/annrheumdis-2018-eular.2637

Journal Title

Annals of Rhuematic Diseases

Department

Dermatology

Recommended Citation

van der Heijde, D., Deodhar, A., FitzGerald, O., Fleischmann, R., Gladman, D., Gottlieb, A. B., Coates, L. C., Hoepken, B., Bauer, L., Peterson, L., Khraishi, M., & Mease, P. J. (2018). Certolizumab Pegol Provides Sustained Remission and Minimal Disease Activity in Patients with Psoriatic Arthritis Over 4 Years' Treatment. Annals of Rhuematic Diseases, 77 (Suppl. 2), 1027. https://doi.org/10.1136/annrheumdis-2018-eular.2637